WO2007029898A1 - Water soluble chitosan nanoparticle for delivering an anticancer agent and preparing method thereof - Google Patents
Water soluble chitosan nanoparticle for delivering an anticancer agent and preparing method thereof Download PDFInfo
- Publication number
- WO2007029898A1 WO2007029898A1 PCT/KR2005/002988 KR2005002988W WO2007029898A1 WO 2007029898 A1 WO2007029898 A1 WO 2007029898A1 KR 2005002988 W KR2005002988 W KR 2005002988W WO 2007029898 A1 WO2007029898 A1 WO 2007029898A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- water
- soluble chitosan
- nanoparticle
- anticancer agent
- delivering
- Prior art date
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 141
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 53
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract description 30
- 238000000034 method Methods 0.000 title abstract description 16
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 53
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 52
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 52
- 125000003277 amino group Chemical group 0.000 claims abstract description 18
- 125000001165 hydrophobic group Chemical group 0.000 claims abstract description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 50
- 235000012000 cholesterol Nutrition 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 16
- QNEPTKZEXBPDLF-JDTILAPWSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] carbonochloridate Chemical compound C1C=C2C[C@@H](OC(Cl)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QNEPTKZEXBPDLF-JDTILAPWSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 239000006227 byproduct Substances 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 229920001427 mPEG Polymers 0.000 claims description 9
- 238000000502 dialysis Methods 0.000 claims description 8
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 claims description 7
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- 230000001093 anti-cancer Effects 0.000 abstract description 8
- 239000012153 distilled water Substances 0.000 abstract description 7
- 210000004881 tumor cell Anatomy 0.000 abstract description 6
- 239000000969 carrier Substances 0.000 abstract description 3
- 238000004108 freeze drying Methods 0.000 abstract description 3
- 125000000524 functional group Chemical group 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 230000008685 targeting Effects 0.000 abstract description 3
- 238000009825 accumulation Methods 0.000 abstract description 2
- 239000006185 dispersion Substances 0.000 abstract description 2
- 229940127084 other anti-cancer agent Drugs 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 24
- 239000000243 solution Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 13
- 230000002209 hydrophobic effect Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- LCTORNIWLGOBPB-GASJEMHNSA-N (3r,4s,5s,6r)-2-amino-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound NC1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LCTORNIWLGOBPB-GASJEMHNSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000007908 nanoemulsion Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- -1 amine salt Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000000089 atomic force micrograph Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- XJKVPKYVPCWHFO-UHFFFAOYSA-N silicon;hydrate Chemical compound O.[Si] XJKVPKYVPCWHFO-UHFFFAOYSA-N 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a water soluble chitosan nanoparticle (WSC-NP) for delivering an anticancer agent and a preparing method thereof, more precisely, a water soluble chitosan nanoparticle for delivering an anticancer agent which has function of targeting on a wanted area by introducing a functional group in the location of highly reactive amine group and becomes an excellent gene carrier with the use of water soluble chitosan (WSC) since the water soluble chitosan itself can combined with DNA having a negative electric charge(-) owing to the very strong positive electric charge(+) of its amine group, and a preparing method thereof.
- WSC-NP water soluble chitosan nanoparticle
- Chitosan is formed by ⁇ -1,4 bond of pyranose monomers of glucosamine, having over 5,000 residues of glucosamine. Its molecular weight is over one million.
- a biopolymer belonging to polysaccharide having polycations chitosan is extracted from aquatic products such as Crustacea like crab or shrimp and a squid. It has a similar molecular structure to that of cellulose, a kind of polysaccharide, indicating that it has an excellent biocompatibility without rejection by immune reaction. So, chitosan has been widely used in medical industry and recently attested by FDA, U.S.A. to be safe food. Thus, chitosan is expected to be a relevant material applicable to bioindustry and biomedical industry in the 21 st century.
- chitosan having a molecular weight ranging from 20,000 to 100,000 is known to have very strong physiological activities, so the chitosan can be applied to the production of health food, food and beverages, cosmetics, sanitation and medical supplies.
- a preparing method for a pure water soluble free amine chitosan having a molecular weight ranging 1,000 ⁇ 100,000 Da was reported, which includes the steps of 1) organic or inorganic acid salt solution of chitosan oligosaccharide is treated with trialkyl amine, 2) an organic solvent is added to the above solution to separate organic or inorganic acid linked with chitosan oligosaccharide which becomes trialcohol amine salt, and then, recover the chitosan oligosaccharide without organic or inorganic salt, 3) the solution of chitosan oligosaccharide without acid is treated with inorganic acid and purified by activated carbon/ion exchange resin column, resulting in a pure water soluble free amine chitosan having a molecular weight of 1,000 ⁇ 100,000 Da.
- paclitaxel Although paclitaxel, attested by FDA, U.S.A. in 1992, has a very excellent anticancer activity comparing to other conventional anticancer agents, it has a serious problem of side effects resulted from that it has to be dispersed in a mixed solution of cremophore EL (polyethoxylated oil) and ethanol (50:50) to be used as an injection because paclitaxel is hydrophobic so that it is not dispersed in water at all.
- cremophore EL polyethoxylated oil
- ethanol 50:50
- HSA human serum albumin
- the present invention provides a water soluble chitosan nanoparticle for effective delivering an anticancer agent and a preparation method for the same, in which a water soluble chitosan is used as a basic component for an anticancer agent carrier, a water soluble chitosan itself becomes an outstanding gene carrier by being combined with a DNA having a negative charge (-) owing to the amine group of chitosan having a very strong positive charge (+), and the carrier is given function of targeting on a wanted area by introducing a functional group in highly reactive free amine group.
- FIG. 1 is a graph showing the MTT test results of a WSC
- FIG. 2-3 is a set of graphs showing the FT-IR spectrum of a WSC conjugated with
- FIG. 4-6 is a set of graphs showing the H-NMR spectrum of a WSC wherein a hy- drophilic group MPEG p-NP and a hydrophobic group cholesteryl chloroformate are conjugated
- FIG. 7 and FIG. 8 are photographs showing the surface of WSC-NP of the present invention taken by TEM and AFM
- FIG. 9-10 is a set of graphs showing the results of heat analysis before enveloping paclitaxel (FIG. 9) and after enveloping paclitaxel (FIG. 10), [21] FIG.
- FIG. 11-12 is a set of graphs showing the results of mass analysis of both paclitaxel enveloped in a WSC-NPT and a standard paclitaxel
- FIG. 13 is a graph showing the survival rate of mice according to the treatment of different drugs
- FIG. 14 is a graph showing the growth of a tumor after the administration of a drug to a mouse
- FIG. 15 is a graph showing the weight changes after the administration of a drug of a mouse transplanted with a tumor.
- the present invention provides a water-soluble chitosan nanoparticle (WSC-NP) for delivering an anticancer agent that is prepared by introducing a hydrophobic group such as cholesterol and methoxy poly (ethylene glycol) p-nitrophenyl carbonate (MPEG p-NP) in water-soluble chitosan chain.
- WSC-NP water-soluble chitosan nanoparticle
- MPEG p-NP methoxy poly (ethylene glycol) p-nitrophenyl carbonate
- cholesteryl chloroformate seals paclitaxel, a hydrophobic medicine, to be carried, and MPEG increases solubility of the cholesterol, resulting in making paclitaxel to be circulated in blood for a long time and protecting the nanoparticle from the attack of reticuloendothelial system (RES) and macrophages.
- RES reticuloendothelial system
- the present invention also provides a preparation method of a water-soluble nanoparticle for delivering an anticancer agent containing hydrophobic core which includes the following steps:
- a hydrophilic group methoxy poly (ethylene glycol) p- nitrophenyl carbonate (MPEG p-NP) and a hydrophobic group cholesteryl chloroformate were combined with free amine group of a water-soluble chitosan, resulting in a water-soluble chitosan nanoparticle.
- MPEG p-NP a hydrophilic group methoxy poly (ethylene glycol) p- nitrophenyl carbonate
- a hydrophobic group cholesteryl chloroformate were combined with free amine group of a water-soluble chitosan, resulting in a water-soluble chitosan nanoparticle.
- paclitaxel was effectively enveloped with the nanoparticles, resulting in a water-soluble chitosan nanopaclitaxel (WSC-NPT) that could be easily re-dispersed in water.
- the water-soluble chitosan nanopaclitaxel can be produced as follows.
- methoxy poly (ethylene glycol) p-nitrophenyl carbonate (MPEG p-NP) is added to a water-soluble chitosan to form amide bond, and the byproduct 'p-nitrophenyl group' is eliminated by dialysis with ice water for 48 hours. The remaining by-products are completely eliminated by purifying the reaction solution with anhydrous ethanol.
- cholesteryl chloroformate is added to the above reaction solution to form another amide bond between free amine group and cholesteryl chloroformate, resulting in a water-soluble chitosan nanoparticle having hydrophobic core (see Scheme 1).
- an anticancer agent paclitaxel
- the agent is enveloped in cholesterol, a hydrophobic group of the above water-soluble chitosan nanoparticle, leading to the production of water-soluble chitosan nanopaclitaxel.
- Water-soluble chitosan used in the present invention as an anticancer agent carrier is adequate to deliver an anticancer agent because it contains a highly reactive free amine group.
- a water-soluble chitosan nanoparticle prepared in the present invention using a water- soluble chitosan is also accumulated more in tumor cells than in normal cells, comparing to other conventional anticancer agent carriers, suggesting its excellent anticancer effect.
- cancer cells are a little more acidic than neighboring cells.
- a water-soluble chitosan having 6.5 pKa is stabilized better in weak acid, indicating that it is able to target on cancer cells rather than normal cells. Therefore, the water-soluble chitosan nanoparticle is accumulated more in cancer cells.
- Water-soluble chitosan nanopaclitaxel containing paclitaxel therein is characterized by excellent re-dispersion force in distilled water after being freeze-dried and also has other merits of natural polymeric materials like a water-soluble chitosan.
- Example 1 Preparation of a water-soluble chitosan nanoparticle 1
- a water-soluble chitosan with molecular weight of 18 kDa and degree of deacetylation of 87% was supplied from KITTOLIFE Co. Ltd.
- Methoxy poly (ethylene glycol) p-nitrophenyl carbonate (MPEG p-NP)), hydrophilic moiety was purchased from Sigma Co. and cholesteryl chloroformate, hydrophobic group, was purchased from Aldrich Co.
- Dialysis tubing (MWCO 12,000) was commercially obtained from Spectrum Co. All other chemicals were reagent grade and used as received.
- step 1 Preparation of a water-soluble chitosan nanoparticle was carried out in the following steps.
- step 1 0.1 g of water-soluble chitosan was dissolved in 15 ml of PBS (pH 7.0 ⁇ 8.0), followed by stirring for one hour.
- step 2 0.5 g of Methoxy poly (ethylene glycol) p-nitropheyl carbonate (MPEG p-NP) was dissolved in PBS (pH 8.0), which was dropped slowly to the above chitosan reaction solution while the solution was stirring.
- MPEG p-NP Methoxy poly (ethylene glycol) p-nitropheyl carbonate
- a white product obtained through freeze-drying in the above step 1 was dissolved in 15 ml of PBS (pH 7.0 ⁇ 8.0), followed by stirring for one hour. Cholesteryl chloroformate was dissolved in 1 ⁇ 2 ml of anhydrous DMF by 1.0 per 10 chitosan glucose amine monomers. The cholesteryl chloroformate solution was slowly dropped into the above reaction solution while the reaction solution was stirring for 2 hours. Upon completing the reaction, dialysis was performed with distilled water for 24 hours. Centrifugation was then performed at 10,000 rpm for 10 minutes, followed by filtering with 0.45 D syringe filter and freeze-drying. A final product, a white water-soluble chitosan nanoparticle, was obtained.
- a water-soluble chitosan nanoparticle was prepared by the same method as described in the above Example 1 except that 1.5 cholesteryl chloroformate per 10 chitosan glucose amine monomers were used. [50]
- a water-soluble chitosan nanoparticle was prepared by the same method as described in the above Example 1 except that 1.8 cholesteryl chloroformate per 10 chitosan glucose amine monomers were used.
- MTT assay was performed to investigate toxicity of a water-soluble chitosan used in the present invention. 293T cells were put in a 96 well plate by 5x10 cells/well, followed by culture for 24 hours. [65] Water-soluble chitosans having different weight average molecular weight (Mw)
- OD means the value of OD measured in wells treated with water-soluble
- 570 chitosan and OD means the value of OD measured in wells treated with
- FIG. 2 shows the FT-IR spectrum of water-soluble chitosan, in which peaks of amine group and amide group of glucose amine monomer were clearly shown differently at 1539 cm “ and 1635 cm “ , respectively. As shown in FIG.
- FIG. 4-6 shows H-NMR spectrum of a water-soluble chitosan modified with a hydrophilic group MPEG and a hydrophobic group cholesterol.
- FIG. 4 shows a spectrum showing peaks of cholesterol not reacted around 1.5 ⁇ 0.5 ppm, which was taken after dissolving WSC-NP in CDCI without removing the remaining cholesterol.
- the strong peak observed at the region of 1.8 ppm suggested that hydrophobic core was formed by the linkage of cholesterol, a hydrophobic group, to a chain of a water-soluble chitosan.
- FIG. 5 shows H-NMR spectrum of WSC-NP, which was taken after purifying the particle with ethyl ether to eliminate the remaining cholesterol not reacted. As shown in the graph, the peak of cholesterol at 1.5 ⁇ 0.5 ppm disappeared and a specific peak at 1.8 ppm was clearly shown, meaning that the hydrophobic core was formed.
- FIG. 7 shows the configuration of the surface of water-soluble chitosan nanoparticle investigated by TEM.
- FIG. 7 shows TEM photographs of water-soluble chitosan nanoparticle.
- FIG. 8 shows AFM observation of water-soluble chitosan nanoparticle.
- the water-soluble chitosan nanoparticle had spherical smooth surface and the size of the particle decreased with the increase of substitution with cholesterol, a hydrophobic group, because the particles were densified by cholesterol, which was the same result as obtained from TEM analysis.
- PCS Photon correlation spectroscopy
- Water-soluble chitosan was modified with MEPG, a hydrophilic group, and cholesterol, a hydrophobic group, to envelope paclitaxel, a hydrophobic anticancer agent. As shown in Table 1, the size of the particle decreased with the increase of substitution with cholesterol and critical aggregation concentration (CAC) was also reduced. The result indicates that the nanoparticles are formed even in the low concentration when the level of cholesterol, a hydrophobic group, is increased. As a result of Zeta potential measurement, it was confirmed that a positive charge of a water-soluble chitosan was decreased by the substitution of amine group with MPEG and cholesterol.
- CAC critical aggregation concentration
- Tm of WSC-NP not containing paclitaxel therein was detected at around 50 0 C (see FIG. 9).
- Tm of WSC-NP was detected at around 50 0 C and at the same time Tm of paclitaxel was seen at around 240°C (see FIG. 10).
- Tm of paclitaxel contained in a water-soluble chitosan nanopaclitaxel was higher than that of original paclitaxel (215°C), which might be because that paclitaxel was completely enveloped in the hydrophobic core ofwater-soluble chitosan nanoparticle.
- Table 2 shows loading content and loading efficiency of enveloped paclitaxel in a water-soluble chitosan nanopaclitaxel prepared in the above Example 4 ⁇ Example 6.
- the loading content and the loading efficiency of paclitaxel were increased with the increase of substitution with cholesterol, a hydrophobic group, in the chains of a water- soluble chitosan harboring MPEG. And the results were confirmed again by the quantification by HPLC as shown in FIG. 11-12.
- characteristic peak of paclitaxel(12) was detected at 3.4 min and (11) shows the quantified paclitaxel enveloped in a water-soluble chitosan nanopaclitaxel.
- the results indicate that the loading content of paclitaxel was increased with the increase of cholesterol content, which was resulted from the hydrophobic interaction between water-soluble chitosan nanoparticle and cholesterol.
- mice Female BALB/c mice (average weight: 20 g) were injected subcutaneously in the flank with CT-26 mourine tumor cells (5x10 cells/mouse). When the tumor was growing to the size of 3 mm x 3 mm, the mice were divided into two groups; an experimental group and a control group. Each group was filled with 8 mice having a tumor and they were marked in their ears for the observation. 15 days after the transplantation, the administration (an intravenous injection) of drug and vehicle began. Each test drug was administered both with low dose of 2 mg/kg and with high dose of 10 mg/kg every three days four times total for 12 days. Only vehicle (cremophor: dehydrated ethyl alcohol, 1:1 v/v) was administered to a control group. Death rate of mice was checked every day and the growth of a tumor was measured using caliper measurement device at two or three day interval. Tumor volume was calculated by the following Formula 2.
- FIG. 13 is a graph showing the survival rate of mice each administered with paclitaxel and a water-soluble chitosan nanopaclitaxel. Control group mice lost their lives faster than any other group. Mice administered with high dose (10 mg/kg) died much earlier within 40 days than three other groups, but the survival rates of three groups each treated with 2 mg/kg and 10 mg/kg of paclitaxel and 2 mg/ kg of a water-soluble chitosan nanopaclitaxel were not much different from each other. An experimental group treated with high dose (10 mg/kg) of a water-soluble chitosan nanopaclitaxel showed the highest survival rate among groups during the whole period of experiments.
- FIG. 14 is a graph showing the anticancer activities of paclitaxel and a water- soluble chitosan nanopaclitaxel to CT-26 tumor models.
- Tumor volume was measured from the 15 day after tumor cell transplantation.
- paclitaxel and a water-soluble chitosan nanopaclitaxel were administered with low dose of 2 mg/kg, the tumor volume was not much different between them.
- the drugs were administered with high dose of 10 mg/kg, the tumor volume in mice treated with paclitaxel was remarkably decreased, comparing to other groups each treated with vehicle only, 2 mg/kg of paclitaxel and 2 mg/kg of a water-soluble chitosan nanopaclitaxel.
- the growth of a tumor was excellently inhibited, but 30 days later the tumor began growing again.
- the anticancer activity of a water-soluble chitosan nanopaclitaxel was the highest with the dose of 10 mg/kg.
- the tumor growth was constantly inhibited up to 38 days but began after 40 days.
- FIG. 15 is a graph showing the weight changes after the administration of a drug to mice transplanted with a tumor.
- weight changes among the groups control, 2 mg/kg of paclitaxel treating group, 2 mg/kg of a water-soluble chitosan nanopaclitaxel treating group
- the weight of mice treated with high dose of a water-soluble chitosan nanopaclitaxel was greatly decreased.
- the results indicate that the administration of a water-soluble chitosan nanopaclitaxel with high dose decreases the size of tumor, resulting in the inhibition of weight gaining.
- water-soluble chitosan nanoparticle for delivering an anticancer agent of the present invention is useful for the production of a water-soluble chitosan nanopaclitaxel in which an anticancer agent, paclitaxel, is successfully enveloped by introducing a hydrophilic group and a hydrophobic group into the region of highly reactive free amine group by taking advantage of a water-soluble chitosan.
- the water-soluble chitosan nanopaclitaxel has many advantages of a polymer because it is produced based on a natural polymer 'a water-soluble chitosan'.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a water soluble chitosan nanoparticle (WSC-NP) for delivering an anticancer agent and a preparing method thereof, more precisely, a water soluble chitosan nanoparticle for delivering an anticancer agent which has function of targeting on a wanted area by introducing a functional group in the location of highly reactive amine group and becomes an excellent gene carrier with the use of water soluble chitosan since the water soluble chitosan itself can combined with DNA having a negative electric charge(-) owing to the very strong positive electric charge(+) of its amine group, and a preparing method thereof. Therefore, a water-soluble chitosan nanoparticle for delivering an anticancer agent of the present invention can effectively envelope paclitaxel by introducing hydrophilic and hydrophobic groups in the position of highly reactive amine group of the water-soluble chitosan. A water soluble chitosan nanopaclitaxel prepared as the above has an excellent re-dispersion force, after freeze-drying, in distilled water and has an outstanding anticancer effect with its accumulation in tumor cells greater than that of the other anticancer agent carriers.
Description
Description
WATER SOLUBLE CHITOSAN NANOPARTICLE FOR DELIVERING AN ANTICANCER AGENT AND PREPARING
METHOD THEREOF
Technical Field
[1] The present invention relates to a water soluble chitosan nanoparticle (WSC-NP) for delivering an anticancer agent and a preparing method thereof, more precisely, a water soluble chitosan nanoparticle for delivering an anticancer agent which has function of targeting on a wanted area by introducing a functional group in the location of highly reactive amine group and becomes an excellent gene carrier with the use of water soluble chitosan (WSC) since the water soluble chitosan itself can combined with DNA having a negative electric charge(-) owing to the very strong positive electric charge(+) of its amine group, and a preparing method thereof.
[2]
Background Art
[3] Chitosan is formed by β-1,4 bond of pyranose monomers of glucosamine, having over 5,000 residues of glucosamine. Its molecular weight is over one million. As a biopolymer belonging to polysaccharide having polycations, chitosan is extracted from aquatic products such as Crustacea like crab or shrimp and a squid. It has a similar molecular structure to that of cellulose, a kind of polysaccharide, indicating that it has an excellent biocompatibility without rejection by immune reaction. So, chitosan has been widely used in medical industry and recently attested by FDA, U.S.A. to be safe food. Thus, chitosan is expected to be a relevant material applicable to bioindustry and biomedical industry in the 21st century.
[4] In particular, chitosan having a molecular weight ranging from 20,000 to 100,000 is known to have very strong physiological activities, so the chitosan can be applied to the production of health food, food and beverages, cosmetics, sanitation and medical supplies.
[5] Although the above promising characteristics of chitosan, it has not been applied successfully to the bioindustry since it is an insoluble in water owing to the strong hydrogen bond with neighboring molecules and organic acids including lactic acid, acetic acid, propionic acid, formic acid, ascorbic acid and tartaric acid, and inorganic acids including hydrochloric acid, nitric acid and sulfuric acid had to be used to dissolve chitosan. In order to overcome the problem, the present inventors have developed a water-soluble chitosan and applied for a patent (Korea Patent Application Nos. 2001-0059282 and 2001-0070052).
[6] In the above patents, a preparing method for a pure water soluble free amine chitosan having a molecular weight ranging 1,000 ~ 100,000 Da was reported, which includes the steps of 1) organic or inorganic acid salt solution of chitosan oligosaccharide is treated with trialkyl amine, 2) an organic solvent is added to the above solution to separate organic or inorganic acid linked with chitosan oligosaccharide which becomes trialcohol amine salt, and then, recover the chitosan oligosaccharide without organic or inorganic salt, 3) the solution of chitosan oligosaccharide without acid is treated with inorganic acid and purified by activated carbon/ion exchange resin column, resulting in a pure water soluble free amine chitosan having a molecular weight of 1,000 ~ 100,000 Da.
[7] Although paclitaxel, attested by FDA, U.S.A. in 1992, has a very excellent anticancer activity comparing to other conventional anticancer agents, it has a serious problem of side effects resulted from that it has to be dispersed in a mixed solution of cremophore EL (polyethoxylated oil) and ethanol (50:50) to be used as an injection because paclitaxel is hydrophobic so that it is not dispersed in water at all.
[8] Because of insolubility in water, paclitaxel, a natural material having an anticancer activity, has limitation in use as an injection. Therefore, various systems have been proposed to make injection of paclitaxel possible. For example, human serum albumin (HSA) which is biodegradable and strongly bound to paclitaxel was combined with paclitaxel, followed by sonication, high-pressure homogenization and microflu- idization according to a conventional method, resulting in an emulsion applicable as an injection.
[9] Applicable injections prepared by combination of paclitaxel produced by VivoRx
Pharmaceuticals, Inc. by taking advantage of sonication skill providing an average particle size of under 10 D and human serum albumin particles were reported in U.S. Patent Nos. 5,439,686, 5,498,421, 5,560,933 and WO 94/18954. However, the preparing methods reported in the above patents cannot be used on a large industrial scale. Moreover, the particles resulted from the above methods are too big to be administered to a patient.
[10] Other reports concerning paclitaxel having an average size of under 0.2 D obtained from dissolving freeze-dried powder in sterilized 0.9% NaCl solution and sterilized human serum albumin nano-emulsion have been made in U.S. Patent Nos. 5,916,596, 6,096,331, WO 98/14174 and WO 99/00113 as well. According to the above reports, particles in nano-emulsion obtained through high-pressure homogenization are uniform in size and nanoparticle precipitate is not formed as time passes, indicating the stability of nano-emulsion. However, paclitaxel suspension prepared by mixing with human serum albumin is not available as an injection on industrial scale, yet.
[11] Thus, the present inventors have studied on a method to use chitosan as a paclitaxel
carrier which is applicable to medical industry successfully because chitosan has excellent biocompatibility without rejection by immune reaction as being administered, and have completed this invention by establishing the method. [12]
Disclosure of Invention
Technical Solution [13] It is an object of the invention to provide a water soluble chitosan nanoparticle which makes possible to use highly water soluble chitosan having free amine group as a paclitaxel carrier and a preparation method of the same. [14] In order to achieve the above object, the present invention provides a water soluble chitosan nanoparticle for effective delivering an anticancer agent and a preparation method for the same, in which a water soluble chitosan is used as a basic component for an anticancer agent carrier, a water soluble chitosan itself becomes an outstanding gene carrier by being combined with a DNA having a negative charge (-) owing to the amine group of chitosan having a very strong positive charge (+), and the carrier is given function of targeting on a wanted area by introducing a functional group in highly reactive free amine group.
Brief Description of the Drawings [15] The application of the preferred embodiments of the present invention is best understood with reference to the accompanying drawings, wherein: [16] FIG. 1 is a graph showing the MTT test results of a WSC,
[17] FIG. 2-3 is a set of graphs showing the FT-IR spectrum of a WSC conjugated with
MEPG p-NP, [18] FIG. 4-6 is a set of graphs showing the H-NMR spectrum of a WSC wherein a hy- drophilic group MPEG p-NP and a hydrophobic group cholesteryl chloroformate are conjugated, [19] FIG. 7 and FIG. 8 are photographs showing the surface of WSC-NP of the present invention taken by TEM and AFM, [20] FIG. 9-10 is a set of graphs showing the results of heat analysis before enveloping paclitaxel (FIG. 9) and after enveloping paclitaxel (FIG. 10), [21] FIG. 11-12 is a set of graphs showing the results of mass analysis of both paclitaxel enveloped in a WSC-NPT and a standard paclitaxel, [22] FIG. 13 isa graph showing the survival rate of mice according to the treatment of different drugs, [23] FIG. 14 is a graph showing the growth of a tumor after the administration of a drug to a mouse, [24] FIG. 15 is a graph showing the weight changes after the administration of a drug of
a mouse transplanted with a tumor. [25]
Best Mode for Carrying Out the Invention
[26] Hereinafter, the present invention will be described in more detail.
[27] The present invention provides a water-soluble chitosan nanoparticle (WSC-NP) for delivering an anticancer agent that is prepared by introducing a hydrophobic group such as cholesterol and methoxy poly (ethylene glycol) p-nitrophenyl carbonate (MPEG p-NP) in water-soluble chitosan chain.
[28] The introduced cholesteryl chloroformate seals paclitaxel, a hydrophobic medicine, to be carried, and MPEG increases solubility of the cholesterol, resulting in making paclitaxel to be circulated in blood for a long time and protecting the nanoparticle from the attack of reticuloendothelial system (RES) and macrophages.
[29] The present invention also provides a preparation method of a water-soluble nanoparticle for delivering an anticancer agent containing hydrophobic core which includes the following steps:
[30] 1) Methoxy poly (ethylene glycol) p-nitrophenyl carbonate (MPEG p-NP) is added to a water-soluble chitosan to form amide bond and the by-product, p-nitrophenyl group is eliminated; and
[31] 2) Cholesteryl chloroformate is added to the above reaction solution to form another amide bond between free amine group of the water-soluble chitosan and cholesteryl chloroformate.
[32] p-nitrophenyl group, the by-product of the step 1), is eliminated by dialysis with ice water, and the remaining by-product is completely eliminated by purifying with anhydrous ethanol.
[33] In the present invention, in order to produce a water-soluble chitosan nanopaclitaxel having a cancer treating effect, a hydrophilic group methoxy poly (ethylene glycol) p- nitrophenyl carbonate (MPEG p-NP) and a hydrophobic group cholesteryl chloroformate were combined with free amine group of a water-soluble chitosan, resulting in a water-soluble chitosan nanoparticle. Then, paclitaxel was effectively enveloped with the nanoparticles, resulting in a water-soluble chitosan nanopaclitaxel (WSC-NPT) that could be easily re-dispersed in water.
[34] More precisely, the water-soluble chitosan nanopaclitaxel can be produced as follows. In the first step, methoxy poly (ethylene glycol) p-nitrophenyl carbonate (MPEG p-NP) is added to a water-soluble chitosan to form amide bond, and the byproduct 'p-nitrophenyl group' is eliminated by dialysis with ice water for 48 hours. The remaining by-products are completely eliminated by purifying the reaction solution with anhydrous ethanol. In the next step, cholesteryl chloroformate is added
to the above reaction solution to form another amide bond between free amine group and cholesteryl chloroformate, resulting in a water-soluble chitosan nanoparticle having hydrophobic core (see Scheme 1). Lastly, an anticancer agent (paclitaxel) is given to the above reaction solution, then, the agent is enveloped in cholesterol, a hydrophobic group of the above water-soluble chitosan nanoparticle, leading to the production of water-soluble chitosan nanopaclitaxel.
[35] <Scheme 1> [36]
[37] Water-soluble chitosan used in the present invention as an anticancer agent carrier is adequate to deliver an anticancer agent because it contains a highly reactive free amine group.
[38] Unlike other preparation methods using organic solvents which are harmful to human, the preparation of a water-soluble chitosan nanoparticle of the present invention is carried out in PBS (Phosphate Buffered Saline) solution (pH 7.0 ~ 8.0) under mild conditions, suggesting the processes are safe and simple.
[39] It is generally known that a polymeric drug is accumulated more in tumor cells than in normal cells owing to its EPR (enhanced permeability and retention effect). A water-soluble chitosan nanoparticle prepared in the present invention using a water- soluble chitosan is also accumulated more in tumor cells than in normal cells, comparing to other conventional anticancer agent carriers, suggesting its excellent
anticancer effect. In general, cancer cells are a little more acidic than neighboring cells. A water-soluble chitosan having 6.5 pKa is stabilized better in weak acid, indicating that it is able to target on cancer cells rather than normal cells. Therefore, the water-soluble chitosan nanoparticle is accumulated more in cancer cells.
[40] Water-soluble chitosan nanopaclitaxel containing paclitaxel therein is characterized by excellent re-dispersion force in distilled water after being freeze-dried and also has other merits of natural polymeric materials like a water-soluble chitosan.
[41] Exemplary, non-limiting embodiments of the present invention will now be described more fully hereinafter. This invention may, however, be embodied in many different forms and should not be construed as limited to the exemplary embodiments set forth herein.
[42]
[43] Example 1 : Preparation of a water-soluble chitosan nanoparticle 1
[44] A water-soluble chitosan with molecular weight of 18 kDa and degree of deacetylation of 87% was supplied from KITTOLIFE Co. Ltd. Methoxy poly (ethylene glycol) p-nitrophenyl carbonate (MPEG p-NP)), hydrophilic moiety, was purchased from Sigma Co. and cholesteryl chloroformate, hydrophobic group, was purchased from Aldrich Co. Dialysis tubing (MWCO 12,000) was commercially obtained from Spectrum Co. All other chemicals were reagent grade and used as received.
[45] Preparation of a water-soluble chitosan nanoparticle was carried out in the following steps. In step 1, 0.1 g of water-soluble chitosan was dissolved in 15 ml of PBS (pH 7.0 ~ 8.0), followed by stirring for one hour. 0.5 g of Methoxy poly (ethylene glycol) p-nitropheyl carbonate (MPEG p-NP)was dissolved in PBS (pH 8.0), which was dropped slowly to the above chitosan reaction solution while the solution was stirring. Two hours later, the solution was dialyzed using a molecular cut-off 12,000 g/mol dialysis tube against cold distilled water for 48 hours, resulting in the formation of a clear product in supernatant and by-product in precipitation layer. Those products were separated and a clear supernatant layer was freeze-dried.
[46] A white product obtained through freeze-drying in the above step 1 was dissolved in 15 ml of PBS (pH 7.0 ~ 8.0), followed by stirring for one hour. Cholesteryl chloroformate was dissolved in 1 ~ 2 ml of anhydrous DMF by 1.0 per 10 chitosan glucose amine monomers. The cholesteryl chloroformate solution was slowly dropped into the above reaction solution while the reaction solution was stirring for 2 hours. Upon completing the reaction, dialysis was performed with distilled water for 24 hours. Centrifugation was then performed at 10,000 rpm for 10 minutes, followed by filtering with 0.45 D syringe filter and freeze-drying. A final product, a white water-soluble chitosan nanoparticle, was obtained.
[47]
[48] Example 2: Preparation of a water-soluble chitosan nanoparticle 2
[49] A water-soluble chitosan nanoparticle was prepared by the same method as described in the above Example 1 except that 1.5 cholesteryl chloroformate per 10 chitosan glucose amine monomers were used. [50]
[51] Example 3: Preparation of a water-soluble chitosan nanoparticle 3
[52] A water-soluble chitosan nanoparticle was prepared by the same method as described in the above Example 1 except that 1.8 cholesteryl chloroformate per 10 chitosan glucose amine monomers were used. [53]
[54] Example 4: Preparation of a water-soluble chitosan nanopaclitaxel 1
[55] 25 mg of water-soluble chitosan nanoparticle prepared in the above Example 1 was dispersed in 10 ml of PBS (pH 7.4), followed by stirring at 400C for 30 minutes. 4 mg of paclitaxel was dissolved in 2 ml of ethanol, which was slowly dropped into the above solution, during which sonication was performed using a water type sonicator. Sonication with the above solution was performed by using a bar type sonicator again for 2 seconds, which was repeated 10 times. Dialysis was performed in PBS (pH 7.4). On the next day, dialysis was performed again in distilled water for 12 hours, followed by centrifugation. Then, the product was filtered by 0.45 D syringe filter and freeze-dried, resulting in a water-soluble chitosan nanopaclitaxel containing paclitaxel therein. [56]
[57] Example 5: Preparation of a water-soluble chitosan nanopaclitaxel 2
[58] Water-soluble chitosan nanopaclitaxel was prepared by the same method as described in the above Example 4 except that WSC-NP prepared in the above Example
2 was used. [59]
[60] Example 6: Preparation of a water-soluble chitosan nanopaclitaxel 3
[61] Water-soluble chitosan nanopaclitaxel was prepared by the same method as described in the above Example 4 except that WSC-NP prepared in the above Example
3 was used. [62]
[63] Experimental Example 1: MTT assay
[64] MTT assay was performed to investigate toxicity of a water-soluble chitosan used in the present invention. 293T cells were put in a 96 well plate by 5x10 cells/well, followed by culture for 24 hours. [65] Water-soluble chitosans having different weight average molecular weight (Mw)
(10,000, 20,000 and 50,000, respectively) were added to each well by the con-
centration of 0.1 ~ 100 D/ml, followed by culture at 37°C for 4 hours. 50 D of MTT prepared at the concentration of 3 mg/ml was added thereto, followed by further culture at 37°C for 4 hours. Supernatant was removed. IOOD of DMSO was put in each well of a 96 well plate, which was left for 10 minutes. Then, micro plate reader (VERSA MAX) was used to investigate the results. Cell viability was calculated by the following Formula 1.
[66]
[67] <Formula 1>
[68] Cell viability (%) = (OD (sample)/OD (control)) x 100
[69]
[70] OD (sample) means the value of OD measured in wells treated with water-soluble
570 chitosan and OD (control) means the value of OD measured in wells treated with
570
PBS buffer solution only. The test results are presented in FIG. 1. As shown in FIG. 1, a water-soluble chitosan having weight average molecular weight ranging from 10,000 to 50,000 has no toxicity.
[71]
[72] Experimental Example 2: Measurement of FT-IR and H-NMR spectroscopy
[73] In order to identify the synthesis of water-soluble chitosan nanoparticle prepared in the above Example 1 modified with hydrophobic group and hydrophilic group, FT-IR (Shimadzu, FT-IR 8700) and 1H-NMR spectrometer (Bruker, DRX-500MHz) were used. For H-NMR measurement, water-soluble chitosan nanoparticle was dissolved in CDCl at the concentration of 10 mg/ml and the spectra were performed at 298 K. To investigate the structural characteristics of the water-soluble chitosan nanoparticle prepared in the above Example 1, H-NMR spectra were measured in CDCl and D O. The results are presented in FIG. 2-3 and FIG. 4-6.
[74] FIG. 2 shows the FT-IR spectrum of water-soluble chitosan, in which peaks of amine group and amide group of glucose amine monomer were clearly shown differently at 1539 cm" and 1635 cm" , respectively. As shown in FIG. 3, the introduction of MPEG into a water-soluble chitosan resulted in that a specific peak by aliphatic-CH of MPEG was observed near 2880 cm , the intensity of amine peak near 1539 cm , one of specific peaks of a water-soluble chitosan, was reduced by amide bond between free amine group of a water-soluble chitosan and carbonyl group of MPEG, and the intensity of specific peak of amide was increased, comparing to that of amine group, by a new amide bond between a water-soluble chitosan and MPEG. So, the results indicate that MPEG was successfully conjugated in a water-soluble chitosan.
[75] FIG. 4-6 shows H-NMR spectrum of a water-soluble chitosan modified with a hydrophilic group MPEG and a hydrophobic group cholesterol. In particular, FIG. 4
shows a spectrum showing peaks of cholesterol not reacted around 1.5 ~ 0.5 ppm, which was taken after dissolving WSC-NP in CDCI without removing the remaining cholesterol. Especially the strong peak observed at the region of 1.8 ppm suggested that hydrophobic core was formed by the linkage of cholesterol, a hydrophobic group, to a chain of a water-soluble chitosan. That is, the original peak of hydrophobic cholesterol was hindered by the bond of polymeric chains of a water-soluble chitosan and MPEG, so that those cholesterols formed a hydrophobic core at 1.8 ppm, making a strong characteristic peak of cholesterol there. FIG. 5 shows H-NMR spectrum of WSC-NP, which was taken after purifying the particle with ethyl ether to eliminate the remaining cholesterol not reacted. As shown in the graph, the peak of cholesterol at 1.5 ~ 0.5 ppm disappeared and a specific peak at 1.8 ppm was clearly shown, meaning that the hydrophobic core was formed. FIG. 6 shows H-NMR spectrum obtained after dissolving water-soluble chitosan nanoparticle in D O, which also confirmed that the hydrophobic core was formed in WSC-NP. As shown in the graph, the specific peak by cholesterol completely disappeared and only characteristic peaks of a water- soluble chitosan and MPEG were observed, supporting that the hydrophobic core was formed. All the above results indicate that MPEG and cholesterol were successfully linked to the chains of a water-soluble chitosan.
[76]
[77] Experimental Example 3: Morphology observation of water-soluble chitosan nanoparticle
[78] Morphology of WSC-NP of the present invention was examined with TEM
(transmission electron microscope; JEOL JEM-2000 FX-II) and AFM (atomic force microscope; PARK'S Science Autoprobe CP). A drop of chitosan nanoparticles suspended in 0.01% of phosphotungstic acid (PTA) was placed on a carbon film coated on a copper grid for TEM. For analysis of the AFM image, chitosan nanoparticles of 0.1 mg/ml in distilled water were placed on a silicon water surface and observed at room temperature with cantilever frequencies oscillating between 12 and 24 kHz. FIG. 7 shows the configuration of the surface of water-soluble chitosan nanoparticle investigated by TEM. FIG. 7 shows TEM photographs of water-soluble chitosan nanoparticle. As shown in these photographs, the shape of the water-soluble chitosan nanoparticle was spherical and the sizes were ranged from about 30 - 150 nm in diameter. When the MPEG ratio to glucosamine unit is constant, the more increase the ratio of cholesterol, the smaller size of chitosan nanoparticle due to the increase of hydrophobicity. FIG. 8 shows AFM observation of water-soluble chitosan nanoparticle. In these photographs, it was confirmed that the water-soluble chitosan nanoparticle had spherical smooth surface and the size of the particle decreased with the increase of substitution with cholesterol, a hydrophobic group, because the
particles were densified by cholesterol, which was the same result as obtained from TEM analysis.
[79] [80] Experimental Example 4: Photon correlation spectroscopy (PCS) measurement [81] Photon correlation spectroscopy (PCS) was measured with a Zetasizer 3000 (Malvern instruments, England) with He-Ne laser beam at a wavelength of 633 nm for the determination of surface charge of the WSC-NP of the present invention. The results are presented in Table 1.
[82] [83] Table 1
[84] [85] Water-soluble chitosan was modified with MEPG, a hydrophilic group, and cholesterol, a hydrophobic group, to envelope paclitaxel, a hydrophobic anticancer agent. As shown in Table 1, the size of the particle decreased with the increase of substitution with cholesterol and critical aggregation concentration (CAC) was also reduced. The result indicates that the nanoparticles are formed even in the low concentration when the level of cholesterol, a hydrophobic group, is increased. As a result of Zeta potential measurement, it was confirmed that a positive charge of a water-soluble chitosan was decreased by the substitution of amine group with MPEG and cholesterol.
[86] [87] Experimental Example 5: Differential scanning calorimetry (DSC) measurement [88] Tm of paclitaxel and a water-soluble chitosan nanopaclitaxel were measured using a TA instrument (Dupont, TA 2000) under nitrogen current. The scanning speed was 10°C/min and the range was determined as 20 - 3500C. The results are presented in FIG. 9-10. FIG. 9-10 show the results of heat analysis before (FIG. 9) and after enveloping paclitaxel (FIG. 10). In general, Tm of water-soluble chitosan nanoparticle and paclitaxel was detected at 500C and 215°C respectively. Tm of WSC-NP not containing paclitaxel therein was detected at around 500C (see FIG. 9). In the meantime, in the case of a water-soluble chitosan nanopaclitaxel in which paclitaxel was enveloped already, Tm of WSC-NP was detected at around 500C and at
the same time Tm of paclitaxel was seen at around 240°C (see FIG. 10). Tm of paclitaxel contained in a water-soluble chitosan nanopaclitaxel was higher than that of original paclitaxel (215°C), which might be because that paclitaxel was completely enveloped in the hydrophobic core ofwater-soluble chitosan nanoparticle.
[89] [90] Experimental Example 6: HPLC measurement to quantify the enveloped paclitaxel [91] Paclitaxel enveloped in a water-soluble chitosan nanopaclitaxel prepared in the above Example 4 was quantified by HPLC using phenomenex sphereclone 5 micro ODS(2) 250 x 4.6mm column and 75% methanol as a moving phase. At that time, the flow rate was set to 1.5 ml/min and the temperature was 500C. And UV detector (226 nm) was used for the measurement. Paclitaxel was dissolved in ethanol, making 20 D for injection. The results are presented in Table 2.
[92] [93] Table 2
[94] [95] Table 2 shows loading content and loading efficiency of enveloped paclitaxel in a water-soluble chitosan nanopaclitaxel prepared in the above Example 4 ~ Example 6. The loading content and the loading efficiency of paclitaxel were increased with the increase of substitution with cholesterol, a hydrophobic group, in the chains of a water- soluble chitosan harboring MPEG. And the results were confirmed again by the quantification by HPLC as shown in FIG. 11-12.
[96] As shown in FIG. 11-12, characteristic peak of paclitaxel(12) was detected at 3.4 min and (11) shows the quantified paclitaxel enveloped in a water-soluble chitosan nanopaclitaxel. The results indicate that the loading content of paclitaxel was increased with the increase of cholesterol content, which was resulted from the hydrophobic interaction between water-soluble chitosan nanoparticle and cholesterol.
[97] [98] Experimental Example 7: Anti-tumor efficacy in a tumor induced CT-26 mouse model
[99] Female BALB/c mice (average weight: 20 g) were injected subcutaneously in the
flank with CT-26 mourine tumor cells (5x10 cells/mouse). When the tumor was growing to the size of 3 mm x 3 mm, the mice were divided into two groups; an experimental group and a control group. Each group was filled with 8 mice having a tumor and they were marked in their ears for the observation. 15 days after the transplantation, the administration (an intravenous injection) of drug and vehicle began. Each test drug was administered both with low dose of 2 mg/kg and with high dose of 10 mg/kg every three days four times total for 12 days. Only vehicle (cremophor: dehydrated ethyl alcohol, 1:1 v/v) was administered to a control group. Death rate of mice was checked every day and the growth of a tumor was measured using caliper measurement device at two or three day interval. Tumor volume was calculated by the following Formula 2.
[100]
[101] <Formula 2>
[102] Tumor volume: mm = (Length x width )/2
[103]
[104] A drug or a vehicle was injected into tail vein of a mouse two weeks after tumor transplantation. FIG. 13 is a graph showing the survival rate of mice each administered with paclitaxel and a water-soluble chitosan nanopaclitaxel. Control group mice lost their lives faster than any other group. Mice administered with high dose (10 mg/kg) died much earlier within 40 days than three other groups, but the survival rates of three groups each treated with 2 mg/kg and 10 mg/kg of paclitaxel and 2 mg/ kg of a water-soluble chitosan nanopaclitaxel were not much different from each other. An experimental group treated with high dose (10 mg/kg) of a water-soluble chitosan nanopaclitaxel showed the highest survival rate among groups during the whole period of experiments.
[105] FIG. 14 is a graph showing the anticancer activities of paclitaxel and a water- soluble chitosan nanopaclitaxel to CT-26 tumor models. Tumor volume was measured from the 15 day after tumor cell transplantation. When the two samples, paclitaxel and a water-soluble chitosan nanopaclitaxel, were administered with low dose of 2 mg/kg, the tumor volume was not much different between them. However, when the drugs were administered with high dose of 10 mg/kg, the tumor volume in mice treated with paclitaxel was remarkably decreased, comparing to other groups each treated with vehicle only, 2 mg/kg of paclitaxel and 2 mg/kg of a water-soluble chitosan nanopaclitaxel. When paclitaxel was administered with 10 mg/kg, the growth of a tumor was excellently inhibited, but 30 days later the tumor began growing again. As shown in FIG. 14, the anticancer activity of a water-soluble chitosan nanopaclitaxel was the highest with the dose of 10 mg/kg. When a water-soluble chitosan nanopaclitaxel was administered, the tumor growth was constantly inhibited
up to 38 days but began after 40 days.
[106] FIG. 15 is a graph showing the weight changes after the administration of a drug to mice transplanted with a tumor. As shown in the graph, weight changes among the groups (control, 2 mg/kg of paclitaxel treating group, 2 mg/kg of a water-soluble chitosan nanopaclitaxel treating group) were not significantly different. Though, the weight of mice treated with high dose of a water-soluble chitosan nanopaclitaxel was greatly decreased. The results indicate that the administration of a water-soluble chitosan nanopaclitaxel with high dose decreases the size of tumor, resulting in the inhibition of weight gaining.
[107] Low dose of a water-soluble chitosan nanopaclitaxel cannot inhibit tumor growth and not affect survival rate much either, but high dose of the drug increases survival rate and decreases tumor volume better than original paclitaxel. In conclusion, high dose over 10 mg/kg of a water-soluble chitosan nanopaclitaxel has an excellent anticancer activity.
[108]
Industrial Applicability
[109] As explained hereinbefore, water-soluble chitosan nanoparticle for delivering an anticancer agent of the present invention is useful for the production of a water-soluble chitosan nanopaclitaxel in which an anticancer agent, paclitaxel, is successfully enveloped by introducing a hydrophilic group and a hydrophobic group into the region of highly reactive free amine group by taking advantage of a water-soluble chitosan. The water-soluble chitosan nanopaclitaxel has many advantages of a polymer because it is produced based on a natural polymer 'a water-soluble chitosan'. In detail, it is re- dispersed in distilled water easily after being freeze-dried and is accumulated in tumor cells better than the other anticancer agent carriers. In addition, a water-soluble chitosan is stabilized better in weak acid, so that the particles of the invention target on cancer cells rather than on normal cells, resulting in better accumulation of nanoparticles in cancer cells, indicating that the particles have an excellent anticancer activity.
[110] Those skilled in the art will appreciate that the conceptions and specific embodiments disclosed in the foregoing description may be readily utilized as a basis for modifying or designing other embodiments for carrying out the same purposes of the present invention. Those skilled in the art will also appreciate that such equivalent embodiments do not depart from the spirit and scope of the invention as set forth in the appended claims.
[I l l]
Claims
[1] A water-soluble chitosan nanoparticle (WSC-NP) for delivering an anticancer agent that is prepared by introducing a hydrophobic group such as cholesteryl chloroformate and methoxy poly (ethylene glycol) p-nitrophenyl carbonate (MPEG p-NP) in water-soluble chitosan (WSC) chain.
[2] The water-soluble chitosan nanoparticle for delivering an anticancer agent as set forth in claim 1, wherein the ratio of water-soluble chitosan : methoxy poly (ethylene glycol) : cholesterol is 10:2:1-1.8.
[3] A water-soluble chitosan nanopaclitaxel in which paclitaxel is enveloped in water-soluble chitosan nanoparticle prepared by introducing a hydrophobic group such as cholesteryl chloroformate and methoxy poly (ethylene glycol) p- nitrophenyl carbonate (MPEG p-NP) in water-soluble chitosan (WSC) chain.
[4] A preparation method of a water-soluble nanoparticle for delivering an anticancer agent comprising the following steps:
1) MPEG is added to a water-soluble chitosan to form amide bond and the byproduct, p-nitrophenyl group, is eliminated; and
2) Cholesterol is added to the above reaction solution to form another amide bond between free amine group of the water-soluble chitosan and cholesteryl chloroformate.
[5] The preparation method of a water-soluble nanoparticle for delivering an anticancer agent as set forth in claim 4, wherein the p-nitrophenyl group, the byproduct of the step 1), is eliminated by dialysis with ice water, and the remaining by-products are completely eliminated by purifying with anhydrous ethanol.
[6] The preparation method of a water-soluble nanoparticle for delivering an anticancer agent as set forth in claim 4, wherein the preparation steps are performed in PBS solution.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008529900A JP5116108B2 (en) | 2005-09-09 | 2005-09-09 | Water-soluble chitosan nanoparticles for anticancer drug transmitter and method for producing the same |
| PCT/KR2005/002988 WO2007029898A1 (en) | 2005-09-09 | 2005-09-09 | Water soluble chitosan nanoparticle for delivering an anticancer agent and preparing method thereof |
| GB0707402.4A GB2436745B8 (en) | 2005-09-09 | 2005-09-09 | Method for enhancing the solubility of paclitaxel |
| CN2005800515276A CN101273066B (en) | 2005-09-09 | 2005-09-09 | Water-soluble chitosan nano particle for delivering carcinostatic agent and method for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2005/002988 WO2007029898A1 (en) | 2005-09-09 | 2005-09-09 | Water soluble chitosan nanoparticle for delivering an anticancer agent and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2007029898A1 true WO2007029898A1 (en) | 2007-03-15 |
Family
ID=37835997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2005/002988 WO2007029898A1 (en) | 2005-09-09 | 2005-09-09 | Water soluble chitosan nanoparticle for delivering an anticancer agent and preparing method thereof |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP5116108B2 (en) |
| CN (1) | CN101273066B (en) |
| GB (1) | GB2436745B8 (en) |
| WO (1) | WO2007029898A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL221351B1 (en) * | 2012-03-14 | 2016-03-31 | Politechnika Warszawska | Method for obtaining polysaccharide nanoparticles |
| IN2014DN10322A (en) * | 2012-05-16 | 2015-08-07 | Mewa Singh | |
| KR101457478B1 (en) * | 2013-04-10 | 2014-11-06 | 순천대학교 산학협력단 | Composition for anti-green algae containing water soluble free amine chitosan and method removing green algaes using the same |
| CN106822906B (en) * | 2016-12-30 | 2020-08-04 | 四川大学 | Water-dispersible acid-responsive lymph-targeting slow-release carrier nano-carbon, preparation method and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN191203B (en) * | 1999-02-17 | 2003-10-04 | Amarnath Prof Maitra |
-
2005
- 2005-09-09 JP JP2008529900A patent/JP5116108B2/en active Active
- 2005-09-09 CN CN2005800515276A patent/CN101273066B/en active Active
- 2005-09-09 WO PCT/KR2005/002988 patent/WO2007029898A1/en active Application Filing
- 2005-09-09 GB GB0707402.4A patent/GB2436745B8/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
Non-Patent Citations (3)
| Title |
|---|
| JANG M.-K. AND NAH J.-W.: "Characterization and modification of low molecular water-soluble chitosan for pharmaceutical application", BULL. KOREAN CHEM. SOC., vol. 24, no. 9, 2003, pages 1303 - 1307, XP003010504 * |
| NSEREKO S. AND AMIJI M.: "Localized delivery of paclitaxel in solid tumors from biodegradable chitin microparticle formulations", BIOMATERIALS, vol. 23, no. 13, 2002, pages 2723 - 2731, XP004352581 * |
| REUL-CARIEPY E. ET AL.: "A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel", EUR. J. PHARM. BIOPHARM., 2004, pages 53 - 63, XP004484698 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0707402D0 (en) | 2007-05-23 |
| GB2436745A8 (en) | 2019-03-13 |
| GB2436745B8 (en) | 2019-03-13 |
| JP5116108B2 (en) | 2013-01-09 |
| CN101273066B (en) | 2013-10-16 |
| CN101273066A (en) | 2008-09-24 |
| GB2436745B (en) | 2011-03-16 |
| GB2436745A (en) | 2007-10-03 |
| JP2009507825A (en) | 2009-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7883723B2 (en) | Water soluble chitosan nanoparticle for delivering an anticancer agent and preparing method thereof | |
| Huo et al. | Synthesis and characterization of low-toxic amphiphilic chitosan derivatives and their application as micelle carrier for antitumor drug | |
| Ko et al. | Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly (β-amino ester) block copolymer micelles for cancer therapy | |
| CN101910274B (en) | Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same | |
| Wang et al. | Self-assembled amphiphilic chitosan nanomicelles to enhance the solubility of quercetin for efficient delivery | |
| KR101444274B1 (en) | Block copolymer for drug complex and pharmaceutical composition | |
| Crucho et al. | Formulation of functionalized PLGA polymeric nanoparticles for targeted drug delivery | |
| KR101262056B1 (en) | Glycol chitosan derivative, preparation method of the same and drug delivery system comprising the same | |
| Raja et al. | Self-assembled nanoparticles based on amphiphilic chitosan derivative and arginine for oral curcumin delivery | |
| Chen et al. | Novel hyaluronic acid coated hydrophobically modified chitosan polyelectrolyte complex for the delivery of doxorubicin | |
| WO2007086651A1 (en) | Anti-cancer agent loaded hydrophobic bile acid conjugated hydrophilic chitosan oligosaccharide nanoparticles and preparation method thereof | |
| WO2006041613A2 (en) | Nanoparticles for targeting hepatoma cells | |
| Jung et al. | Self-assembled polymeric nanoparticles of poly (ethylene glycol) grafted pullulan acetate as a novel drug carrier | |
| Jeong et al. | Doxorubicin release from self-assembled nanoparticles of deoxycholic acid-conjugated dextran | |
| CN108339124B (en) | Preparation method and application of two-stage brain-targeted polymer micelle drug delivery system | |
| Kumar et al. | Redox-sensitive nanoparticles based on xylan-lipoic acid conjugate for tumor targeted drug delivery of niclosamide in cancer therapy | |
| CN1698899A (en) | Novel pharmaceutical composition using chitosan or its derivatives as drug carrier | |
| CN101984958A (en) | Nanoscale albendazole micropowder and preparation method thereof | |
| WO2007029898A1 (en) | Water soluble chitosan nanoparticle for delivering an anticancer agent and preparing method thereof | |
| WO2008007932A1 (en) | Chitosan complex containing ph sensitive imidazole group and preparation method thereof | |
| CN113651959A (en) | Nano drug loading system based on amino acid-hydroxy acid copolymer and preparation method and application thereof | |
| RU2529179C1 (en) | Liposome suspension stabiliser and method for production thereof | |
| Kim et al. | Self-assembled nanoparticles of bile acid-modified glycol chitosans and their applications for cancer therapy | |
| KR101323102B1 (en) | Nanoparticles formed by encapsulating an anticancer drug into glycolchitosan-cholanic acid complex and a process for the preparation thereof | |
| CN111419805B (en) | Environment multiple-response type polymer prodrug micelle based on chitosan and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200580051527.6 Country of ref document: CN |
|
| ENP | Entry into the national phase |
Ref document number: 0707402 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20050909 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 0707402.4 Country of ref document: GB |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1952/DELNP/2008 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008529900 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 05808753 Country of ref document: EP Kind code of ref document: A1 |